Inhibition of murine AIDS by reduced glutathione

Anna T. Palamara, Enrico Garaci, Giuseppe Rotilio, Maria R. Ciriolo, Anna Casabianca, Alessandra Fraternale, Luigia Rossi, Giuditta F. Schiavano, Laura Chiarantini, Mauro Magnani

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The imbalance of the redox state in cells and body fluids in HIV-1- infected patients may result in progression of the disease as well as in immunologic disfunctions. In this report, we have evaluated whether the direct administration of high doses of reduced glutathione (GSH) exerts any antiviral activity and/or improves immune functions in a murine immunodeficiency animal model. Intramuscular administration of 50 or 100 mg GSH/mouse for five consecutive days weekly to LP-BM5-infected mice did not show local or systemic signs of acute toxicity. During the first 3 weeks from infection, a period in which clinical signs of disease were not yet detectable, GSH significantly reduced the viral load in lymph nodes and spleen as evaluated by a PCR semiquantitative assay of the proviral DNA content. At 10 weeks a GSH concentration-dependent reduction of splenomegaly, lymphadenopathy and hypergammaglobulinemia was evident in all treated mice. Evaluation of proviral DNA content showed that GSH was effective in inhibiting LP-BM5 infectivity in lymph nodes, spleen, and bone marrow at 100 mg/day, while it was less effective when administered at 50 mg/day. At 10 weeks some animals receiving the highest GSH dose died, thus only the mice receiving 50 mg GSH were followed up to 15 weeks without signs of toxicity. In this case, almost not significant differences among infected untreated or treated animals were observed. Thus, GSH is effective in reducing the proviral DNA load in the first period of infection. These data and the failure of sulfhydryl supplementation to further counteract the progression of disease after 10 weeks of infection suggest that combinations of GSH and other antiviral agents may be useful for improving current antiviral therapies.

Original languageEnglish
Pages (from-to)1373-1381
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume12
Issue number14
Publication statusPublished - Sep 20 1996

Fingerprint

Murine Acquired Immunodeficiency Syndrome
Glutathione
Antiviral Agents
Disease Progression
DNA
Spleen
Infection
Lymph Nodes
Hypergammaglobulinemia
Splenomegaly
Body Fluids
Viral Load
Oxidation-Reduction
HIV-1
Animal Models
Bone Marrow
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Palamara, A. T., Garaci, E., Rotilio, G., Ciriolo, M. R., Casabianca, A., Fraternale, A., ... Magnani, M. (1996). Inhibition of murine AIDS by reduced glutathione. AIDS Research and Human Retroviruses, 12(14), 1373-1381.

Inhibition of murine AIDS by reduced glutathione. / Palamara, Anna T.; Garaci, Enrico; Rotilio, Giuseppe; Ciriolo, Maria R.; Casabianca, Anna; Fraternale, Alessandra; Rossi, Luigia; Schiavano, Giuditta F.; Chiarantini, Laura; Magnani, Mauro.

In: AIDS Research and Human Retroviruses, Vol. 12, No. 14, 20.09.1996, p. 1373-1381.

Research output: Contribution to journalArticle

Palamara, AT, Garaci, E, Rotilio, G, Ciriolo, MR, Casabianca, A, Fraternale, A, Rossi, L, Schiavano, GF, Chiarantini, L & Magnani, M 1996, 'Inhibition of murine AIDS by reduced glutathione', AIDS Research and Human Retroviruses, vol. 12, no. 14, pp. 1373-1381.
Palamara AT, Garaci E, Rotilio G, Ciriolo MR, Casabianca A, Fraternale A et al. Inhibition of murine AIDS by reduced glutathione. AIDS Research and Human Retroviruses. 1996 Sep 20;12(14):1373-1381.
Palamara, Anna T. ; Garaci, Enrico ; Rotilio, Giuseppe ; Ciriolo, Maria R. ; Casabianca, Anna ; Fraternale, Alessandra ; Rossi, Luigia ; Schiavano, Giuditta F. ; Chiarantini, Laura ; Magnani, Mauro. / Inhibition of murine AIDS by reduced glutathione. In: AIDS Research and Human Retroviruses. 1996 ; Vol. 12, No. 14. pp. 1373-1381.
@article{629faf5125144f78b1c386c402dc6f29,
title = "Inhibition of murine AIDS by reduced glutathione",
abstract = "The imbalance of the redox state in cells and body fluids in HIV-1- infected patients may result in progression of the disease as well as in immunologic disfunctions. In this report, we have evaluated whether the direct administration of high doses of reduced glutathione (GSH) exerts any antiviral activity and/or improves immune functions in a murine immunodeficiency animal model. Intramuscular administration of 50 or 100 mg GSH/mouse for five consecutive days weekly to LP-BM5-infected mice did not show local or systemic signs of acute toxicity. During the first 3 weeks from infection, a period in which clinical signs of disease were not yet detectable, GSH significantly reduced the viral load in lymph nodes and spleen as evaluated by a PCR semiquantitative assay of the proviral DNA content. At 10 weeks a GSH concentration-dependent reduction of splenomegaly, lymphadenopathy and hypergammaglobulinemia was evident in all treated mice. Evaluation of proviral DNA content showed that GSH was effective in inhibiting LP-BM5 infectivity in lymph nodes, spleen, and bone marrow at 100 mg/day, while it was less effective when administered at 50 mg/day. At 10 weeks some animals receiving the highest GSH dose died, thus only the mice receiving 50 mg GSH were followed up to 15 weeks without signs of toxicity. In this case, almost not significant differences among infected untreated or treated animals were observed. Thus, GSH is effective in reducing the proviral DNA load in the first period of infection. These data and the failure of sulfhydryl supplementation to further counteract the progression of disease after 10 weeks of infection suggest that combinations of GSH and other antiviral agents may be useful for improving current antiviral therapies.",
author = "Palamara, {Anna T.} and Enrico Garaci and Giuseppe Rotilio and Ciriolo, {Maria R.} and Anna Casabianca and Alessandra Fraternale and Luigia Rossi and Schiavano, {Giuditta F.} and Laura Chiarantini and Mauro Magnani",
year = "1996",
month = "9",
day = "20",
language = "English",
volume = "12",
pages = "1373--1381",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "14",

}

TY - JOUR

T1 - Inhibition of murine AIDS by reduced glutathione

AU - Palamara, Anna T.

AU - Garaci, Enrico

AU - Rotilio, Giuseppe

AU - Ciriolo, Maria R.

AU - Casabianca, Anna

AU - Fraternale, Alessandra

AU - Rossi, Luigia

AU - Schiavano, Giuditta F.

AU - Chiarantini, Laura

AU - Magnani, Mauro

PY - 1996/9/20

Y1 - 1996/9/20

N2 - The imbalance of the redox state in cells and body fluids in HIV-1- infected patients may result in progression of the disease as well as in immunologic disfunctions. In this report, we have evaluated whether the direct administration of high doses of reduced glutathione (GSH) exerts any antiviral activity and/or improves immune functions in a murine immunodeficiency animal model. Intramuscular administration of 50 or 100 mg GSH/mouse for five consecutive days weekly to LP-BM5-infected mice did not show local or systemic signs of acute toxicity. During the first 3 weeks from infection, a period in which clinical signs of disease were not yet detectable, GSH significantly reduced the viral load in lymph nodes and spleen as evaluated by a PCR semiquantitative assay of the proviral DNA content. At 10 weeks a GSH concentration-dependent reduction of splenomegaly, lymphadenopathy and hypergammaglobulinemia was evident in all treated mice. Evaluation of proviral DNA content showed that GSH was effective in inhibiting LP-BM5 infectivity in lymph nodes, spleen, and bone marrow at 100 mg/day, while it was less effective when administered at 50 mg/day. At 10 weeks some animals receiving the highest GSH dose died, thus only the mice receiving 50 mg GSH were followed up to 15 weeks without signs of toxicity. In this case, almost not significant differences among infected untreated or treated animals were observed. Thus, GSH is effective in reducing the proviral DNA load in the first period of infection. These data and the failure of sulfhydryl supplementation to further counteract the progression of disease after 10 weeks of infection suggest that combinations of GSH and other antiviral agents may be useful for improving current antiviral therapies.

AB - The imbalance of the redox state in cells and body fluids in HIV-1- infected patients may result in progression of the disease as well as in immunologic disfunctions. In this report, we have evaluated whether the direct administration of high doses of reduced glutathione (GSH) exerts any antiviral activity and/or improves immune functions in a murine immunodeficiency animal model. Intramuscular administration of 50 or 100 mg GSH/mouse for five consecutive days weekly to LP-BM5-infected mice did not show local or systemic signs of acute toxicity. During the first 3 weeks from infection, a period in which clinical signs of disease were not yet detectable, GSH significantly reduced the viral load in lymph nodes and spleen as evaluated by a PCR semiquantitative assay of the proviral DNA content. At 10 weeks a GSH concentration-dependent reduction of splenomegaly, lymphadenopathy and hypergammaglobulinemia was evident in all treated mice. Evaluation of proviral DNA content showed that GSH was effective in inhibiting LP-BM5 infectivity in lymph nodes, spleen, and bone marrow at 100 mg/day, while it was less effective when administered at 50 mg/day. At 10 weeks some animals receiving the highest GSH dose died, thus only the mice receiving 50 mg GSH were followed up to 15 weeks without signs of toxicity. In this case, almost not significant differences among infected untreated or treated animals were observed. Thus, GSH is effective in reducing the proviral DNA load in the first period of infection. These data and the failure of sulfhydryl supplementation to further counteract the progression of disease after 10 weeks of infection suggest that combinations of GSH and other antiviral agents may be useful for improving current antiviral therapies.

UR - http://www.scopus.com/inward/record.url?scp=0029793861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029793861&partnerID=8YFLogxK

M3 - Article

C2 - 8891117

AN - SCOPUS:0029793861

VL - 12

SP - 1373

EP - 1381

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 14

ER -